Clinical trials · Ohio
Metastatic Melanoma clinical trials in Ohio
We’re tracking 19 recruiting metastatic melanoma studies with a site in Ohio — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Ohio
- NCT04511013RecruitingPhase 2
Trial for BRAF-mutant melanoma spread to the brain
This Phase 2 study tests whether a 3-drug plan (encorafenib + binimetinib + nivolumab) works better than ipilimumab + nivolumab for melanoma that has spread to the brain. If you qualify, you’ll get either treatment and have frequent brain scans to track how well it controls the tumors.
Beavercreek, OhioAges 18 years+ - NCT05588453RecruitingPhase 1/Phase 2
Immunotherapy and temozolomide for melanoma brain metastases
This early-phase study tests an immune cell treatment (natural killer cells) plus temozolomide to treat melanoma that has spread to the brain. It’s for people whose brain spots are getting worse and who are not good candidates for certain types of brain radiation.
Columbus, OhioAges 18 years+ - NCT06060613RecruitingPhase 1/Phase 2
OBX-115 cell therapy for advanced melanoma or lung cancer
This trial tests an experimental cell therapy called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has not responded to standard treatments. The therapy uses your own immune cells to fight the cancer. The study aims to see if it is safe and effective.
Columbus, OhioAges 18 years+ - NCT05727904RecruitingPhase 3
New immunotherapy for advanced melanoma, with or without lifileucel
This trial studies whether adding lifileucel (a patient-specific immune-cell treatment) to pembrolizumab works better than pembrolizumab alone. It’s for people with untreated advanced melanoma that cannot be removed by surgery.
Cincinnati, OhioAges 18–70 - NCT05136196RecruitingPhase 2
Cabozantinib plus nivolumab for advanced melanoma or head-neck cancer
This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.
Centerville, OhioAges 18 years+ - NCT06581406RecruitingPhase 2/Phase 3
RP2 with nivolumab for untreated uveal melanoma
This clinical trial tests a new treatment called RP2 (a virus that attacks cancer cells) combined with nivolumab (an immunotherapy drug) for people with metastatic uveal melanoma who have never had immunotherapy before. It aims to see if this combination can shrink tumors and improve outcomes.
Columbus, OhioAges Any age - NCT05361174RecruitingPhase 1/Phase 2
Testing an IOV-4001 infusion for advanced melanoma or lung cancer
This trial studies how well and how safely an infusion called IOV-4001 works in adults with advanced melanoma or non-small-cell lung cancer that cannot be removed with surgery. It also aims to see what side effects occur and whether the treatment can help control the cancer.
Cincinnati, OhioAges 18–70 - NCT06500455RecruitingPhase 3
Standard vs longer radiation for brain metastases
This trial compares the usual short course of radiation therapy (one session) to a longer course (up to 5 sessions) for people with cancer that has spread to the brain. The goal is to see if the longer course works better and causes fewer side effects.
Avon, OhioAges 18 years+ - NCT04697576RecruitingPhase 1
Flu vaccine injected into melanoma tumors for stage I-IV
This trial tests whether injecting a flu vaccine directly into melanoma tumors helps shrink them. It is for people with stage I to IV melanoma who have at least one tumor that can be injected.
Columbus, OhioAges 18–99 - NCT06743126RecruitingPhase 3
IMA203 vs standard treatment for advanced skin cancer
This trial tests a new cell therapy called IMA203 against standard treatments for people with advanced melanoma (a type of skin cancer) that has spread or can't be removed. It may be an option if you have already tried certain treatments and your cancer has a specific cell marker (HLA-A*02:01).
Cleveland, OhioAges 18 years+ - NCT03947385RecruitingPhase 1/Phase 2
First drug test for metastatic uveal melanoma with specific gene changes
This Phase 1/2 trial studies IDE196 in adults with metastatic uveal melanoma that has certain gene mutations or fusions. It’s mainly testing safety and correct dosing, and may help shrink tumors in patients matched to the tumor’s genetic changes.
Cleveland, OhioAges 18 years+ - NCT06246916RecruitingPhase 3
Testing a new immunotherapy combo for advanced melanoma
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
Cincinnati, OhioAges 18 years+ - NCT05970497RecruitingPhase 1/Phase 2
KB707 trial for advanced solid tumors after other treatments
This early-stage trial tests KB707 in people with locally advanced or metastatic solid tumors that have not responded well to standard treatments. If you qualify, you may receive KB707 to see how well it can shrink tumors or control the disease.
Canton, OhioAges 18 years+ - NCT06022029RecruitingPhase 1
Study of injected ONM-501 alone or with cemiplimab for advanced cancers
This trial tests an injected study drug (ONM-501) alone or with another drug (cemiplimab) for people with advanced solid tumors or lymphomas that haven't responded to other treatments. It aims to find a safe dose and see if the combination helps shrink or control the cancer.
Canton, OhioAges 18 years+ - NCT05538130RecruitingPhase 1
Study medicine for BRAF-mutated advanced solid tumors
This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.
Cleveland, OhioAges 16 years+ - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Cleveland, OhioAges 18 years+ - NCT06805825RecruitingPhase 1
Study of NN3201 for advanced cancers with c-Kit
This trial tests a new drug, NN3201, that targets a protein called c-Kit found on some cancer cells. It may be an option for people with certain advanced solid tumors, including GIST, small cell lung cancer, or other c-Kit-positive cancers, who have already tried standard treatments or cannot take them.
Cleveland, OhioAges 18 years+ - NCT05824975RecruitingPhase 1/Phase 2
Test drug GI-102 alone or with cancer medicines
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
Cleveland, OhioAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Cincinnati, OhioAges Any age
Metastatic Melanoma trials by city in Ohio
Where these studies are running in Ohio
Institutions with a site for the recruiting metastatic melanoma studies listed above.
- The Ohio State University Wexner Medical Center · 10 studies
- Cleveland Clinic · 6 studies
- Case Western Reserve University · 3 studies
- Oncology Hematology Care · 3 studies
- University of Cincinnati Cancer Center-UC Medical Center · 3 studies
- Atrium Medical Center · 2 studies
- Gabrail Cancer Center · 2 studies
- Grady Memorial Hospital · 2 studies
What taking part in a metastatic melanoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Metastatic Melanoma trials in other states
Common questions
- Are there metastatic melanoma clinical trials in Ohio?
- Yes. We're currently tracking 19 recruiting metastatic melanoma studies with a site in Ohio, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic melanoma study in Ohio?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Ohio to take part?
- Not necessarily. These studies have a site in Ohio, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic melanoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic melanoma studies open in Ohio regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.